Authors: Jan Fedacko Daniel Pella Peter Jarcuska Frantisek Sabol Jan Kmec Tomas Lopuchovsky Lucia Merkovska Lucia Jedlickova Martin Janicko Matej Sajty
Publish Date: 2013/01/15
Volume: 30, Issue: 1, Pages: 60-70
Abstract
The efficacy and safety of singlepill amlodipine/atorvastatin for reducing blood pressure BP lowdensity lipoprotein cholesterol LDLC and predicted 10year cardiovascular CV risk have been demonstrated in low CV risk countries The Slovak Trial on Cardiovascular Risk Reduction Following National Guidelines with CaDUET® amlodipine besylate/atorvastatin calcium Pfizer Morrisville PA USA STRONG DUET study evaluated its clinical utility in Slovakia one of the highest CV risk regions in EuropeThis was a twophase study involving 100 outpatient cardiologist and internist departments in Slovakia Phase 1 assessed BP control and CV risk profiles in adults with treated hypertension and phase 2 was an openlabel multicenter observational study In the phase 2 study patients with treated but uncontrolled hypertension and three or more coronary heart disease risk factors received singlepill amlodipine/atorvastatin 5/10 or 10/10 mg for 12 weeks Major outcomes were the percentage of patients achieving target BP ≤140/90 mmHg and/or LDLC ≤3 mmol/L and reductions in predicted 10year CV riskOf the 4672 phase 1 patients 808 had uncontrolled hypertension and 614 had dyslipidemia Of the 1406 phase 2 patients 903 of patients achieved target BP at week 12 663 achieved target LDLC and 607 achieved both The mean 10year CV risk was reduced by 49 P 00001 treatment was welltolerated and safeSinglepill amlodipine/atorvastatin was associated with significant improvements in BP LDLC target attainment and 10year CV risk in patients with uncontrolled hypertension in Slovakia The treatment was welltolerated and safe Use of singlepill amlodipine/atorvastatin in high CVrisk countries could lead to significant improvements in CV risk management
Keywords: